For example, cTnT antibody-modified liposomes can specifically bind cTnT on the surface of cardiomyocytes in vitro (hypoxia-treated primary cardiomyocytes) and in vivo (AMI rat models) to deliver miR-21 mimics to improve cardiac function and reduce infarct size in the treatment of acute myocardial infarction (AMI) (Figure 2B), showing better targeting ability than PEG-modified liposomes [72]. Here, TNNT2 is linked to myocardial infarction.